Miscellaneous

Miscellaneous is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

  • Flucytosine (25 mg/kg PO q6h) exerts its fungicidal effects on susceptible Candida and Cryptococcus spp. by interfering with DNA synthesis.
    • Main clinical uses are in the treatment of cryptococcal meningitis and severe Candida infections in combination with amphotericin B. This agent should not be used alone because of risk for rapid emergence of resistance.
    • Adverse events include dose-related bone marrow suppression and bloody diarrhea due to intestinal flora conversion of flucytosine to 5-fluorouracil.
    • Peak drug concentrations should be kept between 50 and 100 μg/mL. Close monitoring of serum concentrations and dose adjustments are critical in the setting of renal insufficiency. LFTs should be obtained at least once a week.
  • Terbinafine (250 mg PO q24h for 6–12 weeks) is an allylamine antifungal agent that kills fungi by inhibiting ergosterol synthesis. It is FDA approved for the treatment of onychomycosis of the fingernails (6 weeks of treatment) or toenails (12 weeks of treatment). It is not generally used for systemic infections.

    Adverse events include headache, GI disturbances, rash, LFT abnormalities, and taste disturbances. This drug should not be used in patients with hepatic cirrhosis or a CrCl of <50 mL/min. It does not significantly inhibit the metabolism of cyclosporine (15% decrease) or warfarin.

-- To view the remaining sections of this topic, please or --

  • Flucytosine (25 mg/kg PO q6h) exerts its fungicidal effects on susceptible Candida and Cryptococcus spp. by interfering with DNA synthesis.
    • Main clinical uses are in the treatment of cryptococcal meningitis and severe Candida infections in combination with amphotericin B. This agent should not be used alone because of risk for rapid emergence of resistance.
    • Adverse events include dose-related bone marrow suppression and bloody diarrhea due to intestinal flora conversion of flucytosine to 5-fluorouracil.
    • Peak drug concentrations should be kept between 50 and 100 μg/mL. Close monitoring of serum concentrations and dose adjustments are critical in the setting of renal insufficiency. LFTs should be obtained at least once a week.
  • Terbinafine (250 mg PO q24h for 6–12 weeks) is an allylamine antifungal agent that kills fungi by inhibiting ergosterol synthesis. It is FDA approved for the treatment of onychomycosis of the fingernails (6 weeks of treatment) or toenails (12 weeks of treatment). It is not generally used for systemic infections.

    Adverse events include headache, GI disturbances, rash, LFT abnormalities, and taste disturbances. This drug should not be used in patients with hepatic cirrhosis or a CrCl of <50 mL/min. It does not significantly inhibit the metabolism of cyclosporine (15% decrease) or warfarin.

There's more to see -- the rest of this entry is available only to subscribers.